Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

The number of FDA-approved immune checkpoint inhibitors (ICIs) has increased steadily since 2018. As of early this year, 11 ICIs had been approved for a combined 88 cancer indications. However ...

Despite the absence of any approved VISTA inhibitors to date, a growing body of research underscores the potential of targeting this immune checkpoint as a novel approach to overcome tumor immune ...

The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

Despite the absence of any approved VISTA inhibitors to date, a growing body of research underscores the potential of targeting this immune checkpoint as a novel approach to overcome tumor immune ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in ... approval of Optune Lua by the U.S. Food and Drug Administration in October 2024.

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...